Cargando…

Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy

Neurodegenerative diseases like Parkinson’s disease (PD) and Alzheimer’s disease (AD) are considered disorders of multifactorial origin, inevitably progressive and having a long preclinical period. Therefore, the availability of biological markers or biomarkers (BMs) for early disease diagnosis will...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandel, Silvia A., Morelli, Micaela, Halperin, Ilan, Korczyn, Amos D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405324/ https://www.ncbi.nlm.nih.gov/pubmed/23199065 http://dx.doi.org/10.1007/s13167-010-0036-z

Ejemplares similares

Drug treatment of Parkinson's disease
por: Korczyn, Amos D.
Publicado: (2004)

Editorial comments: treatment of motor fluctuations in Parkinson’s disease
por: Korczyn, Amos D.
Publicado: (2011)

ApoE4: an emerging therapeutic target for Alzheimer’s disease
por: Safieh, Mirna, et al.
Publicado: (2019)

Is dementia preventable?
por: Korczyn, Amos D.
Publicado: (2009)

Can the disease course in Parkinson’s disease be slowed?
por: Korczyn, Amos D., et al.
Publicado: (2015)

Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
por: Jellinger, Kurt A., et al.
Publicado: (2018)

Disorders of the Oral Cavity in Parkinson's Disease and Parkinsonian Syndromes
por: Zlotnik, Yair, et al.
Publicado: (2015)

Neurobiology of Parkinson’s Disease
por: Morelli, Micaela, et al.
Publicado: (2023)

Integrating Transcriptomics with Metabolic Modeling Predicts Biomarkers and Drug Targets for Alzheimer's Disease
por: Stempler, Shiri, et al.
Publicado: (2014)

Editorial Comments: Is multiple sclerosis a neurodegenerative or inflammatory disease?
por: Korczyn, Amos D.
Publicado: (2013)

What is new in vascular dementia?
por: Korczyn, Amos D.
Publicado: (2016)

Dementia in the COVID-19 Period
por: Korczyn, Amos D.
Publicado: (2020)

ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment
por: Guekht, Alla, et al.
Publicado: (2017)

MRI parameters of Alzheimer’s disease in an Arab population of Wadi Ara, Israel
por: Bowirrat, Abdalla, et al.
Publicado: (2005)

Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care
por: Golubnitschaja, Olga, et al.
Publicado: (2011)

Mild cognitive impairment: Conceptual, assessment, ethical, and social issues
por: Werner, Perla, et al.
Publicado: (2008)

Lost in space(s): multimodal neuroimaging of disorientation along the Alzheimer’s disease continuum
por: Peters-Founshtein, Gregory, et al.
Publicado: (2023)

A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease
por: Morelli, Micaela, et al.
Publicado: (2012)

Towards a computerized estimation of visual complexity in images: Data to assess the association of computed visual complexity features to human responses in visual tasks
por: Aharonson, Vered, et al.
Publicado: (2020)

Potential Roles of α-amylase in Alzheimer’s Disease: Biomarker and Drug Target
por: Chen, Win Ning, et al.
Publicado: (2022)

Mitochondrial Homeostasis and Signaling in Parkinson’s Disease
por: Scorziello, Antonella, et al.
Publicado: (2020)

Lack of association between angiotensin-converting enzyme and dementia of the Alzheimer’s type in an elderly Arab population in Wadi Ara, Israel
por: Bowirrat, Abdalla, et al.
Publicado: (2005)

Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery
por: Lane, Rachel F, et al.
Publicado: (2013)

Glial Fibrillary Acidic Protein: A Biomarker and Drug Target for Alzheimer’s Disease
por: Ganne, Akshatha, et al.
Publicado: (2022)

Evaluating Lipid‐Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization
por: Williams, Dylan M., et al.
Publicado: (2020)

Mitochondria-Targeted Protective Compounds in Parkinson's and Alzheimer's Diseases
por: Fernández-Moriano, Carlos, et al.
Publicado: (2015)

Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases()
por: Pandian, Sureshbabu Ram Kumar, et al.
Publicado: (2022)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer’s Disease and Parkinson’s Disease
por: Pawlik, Patrycja, et al.
Publicado: (2021)

Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease
por: Mizutani, Yasuaki, et al.
Publicado: (2023)

Brain imaging biomarkers for the Alzheimer’s Prevention Initiative
por: Chen, Kewei, et al.
Publicado: (2012)

New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer’s Disease
por: Penke, Botond, et al.
Publicado: (2023)

Neuroimaging Biomarkers Predicting the Efficacy of Multimodal Rehabilitative Intervention in the Alzheimer’s Dementia Continuum Pathology
por: Di Tella, Sonia, et al.
Publicado: (2021)

Drug targets and predictive biomarkers in the management of metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2012)

Tubulin and Tau: Possible targets for diagnosis of Parkinson’s and Alzheimer’s diseases
por: Salama, Mohamed, et al.
Publicado: (2018)

Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease
por: Kim, Namdoo, et al.
Publicado: (2020)

An Alzheimer’s Disease-Derived Biomarker Signature Identifies Parkinson’s Disease Patients with Dementia
por: Berlyand, Yosef, et al.
Publicado: (2016)

Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
por: Chiu, Pai-Yi, et al.
Publicado: (2022)

Systematic Review on Saliva Biomarkers in Patients Diagnosed with Morbus Alzheimer and Morbus Parkinson
por: Wolgin, Michael, et al.
Publicado: (2022)

New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases
por: Hölscher, Christian
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_eke5ial34it6fqc493qq8cd60s